DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of small-cell lung cancer for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.
DRG Epidemiology's small-cell lung cancer forecast will answer the following questions:
How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with small-cell lung cancer per year?
In developing countries, what impact will economic growth and development have on the number of people diagnosed with small-cell lung cancer per year?
How will improvements in survival change the number of first-line drug-treatment opportunities for small-cell lung cancer?
How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for small-cell lung cancer?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of small-cell lung cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following small cell lung cancer subpopulations:
Drug-treatable prevalent cases by metastatic status
Diagnosed extensive first-line drug-treatable population
Diagnosed incident cases by stage distribution status
Diagnosed prevalent cases by drug treatment potential status
Diagnosed Incidence of Small-Cell Lung Cancer per 100,000 People of All Ages in 2017 and 2027
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Small-Cell Lung Cancer Over the Next Ten Years
Analysis of the Diagnosed Incident Cases of Small-Cell Lung Cancer in 2017 by Disease Stage
Diagnosed Incident Cases
Stage Distribution of Small-Cell Lung Cancer
Recurrent Incident Cases of Small-Cell Lung Cancer
Diagnosed Prevalent Cases
Drug-Treatable Population and Percentage Drug-Treated
Studies Included in the Analysis of Small-Cell Lung Cancer
Studies Excluded from the Analysis of Small-Cell Lung Cancer
Risk/Protective Factors for Small-Cell Lung Cancer
Ema Rodrigues, D.Sc., M.P.H.
Ema Rodrigues, D.Sc., M.P.H., is an epidemiologist with expertise in forecasting incident and prevalent populations in oncology and cardiovascular indications. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables. She completed her master’s and doctoral degrees (M.P.H., D.Sc.) in environmental health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes, including central nervous system cancer, cognitive function, and birth outcomes.
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.